Drug – bio-affecting and body treating compositions – Lymphokine
Reexamination Certificate
2004-04-15
2010-02-16
Spector, Lorraine (Department: 1647)
Drug, bio-affecting and body treating compositions
Lymphokine
C514S012200, C530S399000
Reexamination Certificate
active
07662366
ABSTRACT:
The object of the present invention is to provide a method for treating diabetes which is simple, safe and effective when compared to conventional diabetes treatment. The administration of one or more stem cell-recruiting factors allows a simple and safe repair of disrupted β-cells in pancreatic Langerhans' islets. Thus, the therapeutic agent of the present invention which comprises one or more stem cell-recruiting factors as active ingredients is useful for diabetes treatment. Examples of such a stem cell-recruiting factor include colony-stimulating factors such as G-CSF.
REFERENCES:
patent: 5629286 (1997-05-01), Brewitt
patent: 6001647 (1999-12-01), Peck et al.
patent: 6232288 (2001-05-01), Kojima
patent: 6303146 (2001-10-01), Bonhomme et al.
patent: 6610535 (2003-08-01), Lu et al.
patent: 6759039 (2004-07-01), Tsang et al.
patent: 2004/0136969 (2004-07-01), Hussain
patent: 2001 233784 (2001-08-01), None
patent: WO 02/50263 (2000-12-01), None
patent: WO/2004/030628 (2003-10-01), None
Canturk et al., Effects of rG-CSF on neutrophil functions and bone marrow parameters in diabetic rats. Endocrine Research.(abstract) 25, 381-395, 1999.
Sato et al., Effect of G-CSF on generation of oxygen-derived free radicals and myeloperoxidase activity in neutrophils from poorly controlled NIDDM patients. Diabetes, 46, 133-137, 1997.
Krakowski et al. Granulocyte macrophage-colony stimulating factor (GM-CSF)recruits immune cells to the pancreas and delays STZ-induced diabetes. J Pathol. 16, 103-112, 2002.
Lukic et al., Effector Mechanisms In Low-Dose Streptozotocin-Induced Diabetes, Develop. Immunol., 6, 119-128, 1998.
Dalhoff et al., Inhibition of neotrophil apoptosis and modulation of the nflammatory response by granulocyte colony-stimulating factor in healthy and ethanol-treated human volunteers. J. Infect. Diseases, 178, 891-895, 1998.
Soria et al. Insulin-Secreting Cells Derived From Embryonic Stem Cells Normalize Glycemia in Streptozotocin-Induced Diabetic Mice. Diabetes, 49, 1-6, 2000.
Takano et al., Pleiotropic Effects of Cytokines on Acute Myocardial Infarction: G-CSF asA Novel Therapy for Acute Myocardial Infarction. Curr. Pharm. Drugs, 9, 1121-1127, 2003.
Maedler et al. Glucose-induced βcell production of IL-1βcontributes to glucotoxicity in human pancreatic islets. J. Clinical Investigation, 10, 851-860, 2002.
Yamaoka T., Regeneration therapy of pancreatic beta cells: towards a cure for diabetes? Biochem. Biophys. Res. Commun. 296, 1039-1043, 2002.
Paris et al., Pancreatic β-Cell Neogenesis Revisited. Experim. Diab. Res. 5, 111-121, 2004.
Bernard-Kargar et al., Endocrine Pancreas Plasticity Under Physiologicaland Pathological Conditions. Diabetes, 50 (suppl. 1) S30-S35, 2001.
Andreas Lechner et al., 'Stem/progenitor cells derived from adult tissues: potential for the treatment of diabetes mellitus,Am. J. Physiol. Endocrinol. Metab., 2003, 284(2), 259-266.
Adachi Yuichiro
Kawabe Yoshiki
Browdy and Neimark PLLC
Chugai Seiyaku Kabushiki Kaisha
Spector Lorraine
Stoica Elly-Gerald
LandOfFree
Method of preventing β cell disruption in pancreatic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of preventing β cell disruption in pancreatic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of preventing β cell disruption in pancreatic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4169576